Description
BSE notifies trading members that equity shares of Goldline Pharmaceutical Limited (scrip code 544759, symbol GLPL) will be listed on the SME segment. The date of listing and security details will be communicated via a separate notice.
Summary
BSE Limited has issued a notice informing trading members that the equity shares of Goldline Pharmaceutical Limited will be listed and admitted to dealings on the Exchange. The specific listing date and further security details will be communicated through a separate notice.
Key Points
- Goldline Pharmaceutical Limited equity shares will be listed on the BSE SME segment.
- Scrip Code: 544759 | Symbol: GLPL | ISIN: INE1CLW01015
- The exact listing date has not yet been announced; a separate notice will follow.
- Notice issued by Hardik Bhuta, Assistant Vice President, BSE Limited.
Regulatory Changes
No regulatory changes introduced. This is a standard pre-listing information notice.
Compliance Requirements
Trading members should note the scrip details (code 544759, symbol GLPL, ISIN INE1CLW01015) and await the subsequent notice confirming the listing date before initiating any dealings.
Important Dates
- Notice Date: 18 May 2026
- Listing Date: To be announced via a separate notice
Impact Assessment
Limited market-wide impact. This notice concerns a single SME-segment listing and is informational in nature. Investors interested in Goldline Pharmaceutical Limited should monitor BSE for the follow-up notice confirming the listing date and trading commencement details.
Impact Justification
Routine SME listing notice for a single company; no regulatory changes or broad market impact. Relevant primarily to investors and members tracking Goldline Pharmaceutical's upcoming listing.